This paper is only available as a PDF. To read, Please Download here.
Abstract
Therapy of the 6C3HED lymphoma in syngeneic C3H/HeN mice was studied using tumor-specific
antiserum in combination with adriamycin, cyclophosphamide, or l-asparaginase. Antiserum therapy is only effective in the control of small numbers
of tumor cells, and cell cures were only obtained when this number did not exceed
5 × 105. Complete suppression of larger numbers of tumor cells (106 to 5 × 107) could be achieved with the inclusion of chemotherapy at levels that reduced the
tumor cell number to less than 105 in the case of l-asparaginase and less than 104 with cyclophosphamide and adriamycin. The differences in drug cooperative effectiveness
are likely to be due to drug-induced impairment of macrophage mobilization to the
tumor site.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to SurgeryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The phagocytosis of tumor cells in vitro.Transplantation. 1964; 2: 183
- The combined effect of drugs and tumorspecific antibodies in protection against a mouse lymphoma.Cancer Res. 1974; 34: 3040
- O'Neill GJ: In vivo and in vitro effects of tumor-specific antibodies with chlorambucil.Br J Cancer. 1973; 28 (Suppl):: 285
- Protection of mice against synogeneic lymphomata. II. Collaboration between drugs and antibodies.Br J Cancer. 1974; 30: 305
- Sequential evaluation of general immune competence in cancer patients: correlation with clinical course.Cancer. 1975; 35: 660
- Antibody-mediated target cell lysis by non-immune cells: characterization of the antibody and effector cell populations.Eur J Immunol. 1972; 2: 419
- Suppression of an AKR lymphoma by antibody and chlorambucil.J Natl Cancer Inst. 1975; 55: 1353
- The effect of isoantibodies in vivo on three different transplantable neoplasms in mice.Cancer Res. 1959; 19: 824
- Modification of host defense mechanisms.in: JF III, Holl Frei E Cancer medicine. Lea & Febriger, Publishers, Philadelphia1973: 681
- Macrophage shortage within tumor diminishes effectiveness of IgG1 antibody mediated suppression.in: ed 3. Fed Proc. 36. 1977: 125 (abstract)
- Antibody-mediated suppression of tumor growth. I. Suppresion by murine IgG1 isolated from alloantiserum.J Immunol. 1977; 118: 489
- Antibody-mediated suppression of tumor growth. II. Macrophage and platelet cooperation with murine IgG1 isolated from alloantiserum.J Immunol. 1977; 118: 494
- Antibody-mediated suppression of tumor growth. III. Molecular assay of murine IgG1 alloantibody required to cause tumor suppression in vivo.J Immunol. 1977; 118: 498
- The infleunce of antiserum on the metastates of ascites cells from the Yoshida sarcoma.Experientia. 1966; 22: 300
- The effect of antiserum on the metastases of ascites cells as a function of time.Eur J Cancer. 1967; 3: 165
- Antibody-dependent cell-mediated cytolysis (ADCC): analysis and projections.Prog Allergy. 1977; 22: 1
- Artificial pulmonary metastasis.Cancer. 1978; 41: 827
- Active immunotherapy of L1210 leukemia applied after the graft of tumor cells.Br J Cancer. 1969; 23: 814
- Antilymphocytic leukemia serum and chemotherapy in the treatment of murine leukemia.Cancer. 1968; 22: 1192
- Serologic immunotherapy: results and probable mechanism of action.Cancer. 1974; 34: 175
- Serologic immunotherapy and interaction with radiation.in: Interactions of radiation and host immune defense mechanisms in malignancy. Brookhaven National Laboratory, Washington, DC1944: 363
- Tumor cell cytostasis by macrophages and antibody in vitro. I. Resolution into contact dependent and contact independent steps.J Immunol. 1978; 120: 1560
- Tumor cell cytostasis by macrophages and antibody in vitro. II. Isolation and characterization of suppressed cells.J Immunol. 1978; 120: 1567
- Serochemotherapy against a Moloney-virus-induced leukemia.Cancer Res. 1973; 63: 1854
- Passive immunotherapy for mouse leukemias with antisera of “directed” specificity: synergism with the action of cyclophosphamide.Cancer Treat Rep. 1977; 61: 1499
- Passive immunotherapy of cancer in animals and man.Adv Cancer Res. 1977; 25: 323
- Correlation between lipid synthesis in tumor cells and their sensitivity to humoral immune attack.Science. 1977; 197: 773
- Enhancing effect of metabolic inhibitors on the killing of tumor cells by antibody and complement.Cancer Res. 1975; 35: 3195
- Antibody-mediated suppression of grafted lymphoma cells. I. Participation of host factor(s) other than complement.in: ed 3. Proc Soc Exp Biol Med. 139. 1972: 684
- Antibody-mediated suppression of lymphoma: participation of platelets, lymphocytes and nonphagocytic macrophages.in: ed 3. Proc Nat Acad Sci. 71. 1974: 163
- Antibodymediated suppression of grafted lymphoma cells. II. Participation of macrophages.J Exp Med. 1972; 136: 375
- Antibody-mediated suppression of grafted lymphoma. III. Evaluation of the role of thymic function, non-thymusderived lymphocytes, macrophages, platelets and polymorphonuclear leukocytes in syngeneic and allogeneic hosts.J Immunol. 1975; 114: 1255
- Antibody-mediated suppression of grafted lympyoma. IV. Influence of time of tumor residency in vivo and tumor size upon the effectiveness of suppression by syngeneic antibody.J Exp Med. 1976; 144: 1274
- Immunotherapy of cancer with antibody.Science (Washington). 1976; 144: 1274
- On the mechanisms of tumor immunity: the role of antibody and nonimmune effectors.Prog Allergy. 1978; 25: 163
- Immunodepression after major surgery in normal patients.Surgery. 1975; 78: 363
- Defective immune effector function in patients with neoplastic and immune deficiency disease.in: Bellanti JA Dayton DH The phagocytic cell in host resistance. Raven Press, New York1975: 267
- An inhibitor of macrophage chemotaxis produced by neoplasms.Science (Washington). 1976; 192: 370
- Considerations in the interactions of radiation and immunotherapy.in: Interactions of radiation and host immune defense mechanisms in malignancy. Brookhaven National Laboratory, New York1974: 130
Article info
Publication history
Accepted:
May 1,
1979
Footnotes
☆Supported in part by U.S. Public Health Service grant No. 1R01 CA-14113 from the National Institutes of Health, Bethesda, Md., a grant from the Maryland Division of the American Cancer Society, and a grant from the Leukemia Research Foundation, Inc., Chicago, Ill.
Identification
Copyright
© 1980 Published by Elsevier Inc.
